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Angiogenesis plays a key role in several rheumatic diseases, including rheumatoid arthritis, osteoarthritis, ankylosing
spondylitis, systemic sclerosis, systemic lupus erythematosus, and vasculitides. An imbalance between angiogenic
inducers and inhibitors seems to be a critical factor in pathogenesis of these diseases. Macrophages promote
angiogenesis during rheumatoid arthritis. In addition, macrophages can produce a variety of pro-angiogenic factors
that have been associated with the angiogenic response occurring during other rheumatic diseases. Lastly,
macrophages could be a target in the treatment of rheumatoid arthritis and other rheumatic diseases. Nevertheless,
further studies are needed to better elucidate the exact role of macrophage in angiogenesis in these diseases.
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Macrophages are a population of cells derived from
CD34 positive bone marrow progenitors, which differen-
tiate to form blood pro-monocytes. Then pro-monocytes
develop into monocytes and extravasate into tissues
where they become “resident” tissue macrophages. Even
if “resident” macrophages are characterized by different
phenotypes within tissues, from that of Kupferr cells in
the liver, microglial cells in the brain, and Langerhans
cells in the skin, they share common aspects, such as
their capacity to influence normal cell turnover and
tissue remodeling, to counteract microbial infections,
and to facilitate repair in sites of injury [1].
Macrophages may be recruited as consequence of any
local disturbance of tissue homeostasis, including normal
cell turnover or wounding, infections, immune response
and malignancy. After recruitment, macrophages become
“activated macrophages” showing different phenotypes in
relation to the nature of the recruiting stimulus and the
location.
As consequence of the variety of secretory products,
anatomic diversity and functional heterogeneity, macro-
phages are involved in different physiological mechanisms
and plays a key role in the aetiology and pathogenesis of* Correspondence: domenico.ribatti@uniba.it
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reproduction in any medium, provided the ornumerous diseases. There are numerous evidences that
macrophages are involved in both physiological and
pathological angiogenesis [2,3].
Activated macrophages are generally categorized in two
types, M1 (classically activated) and M2 (alternatively
activated) [4,5]. M2 macrophages are further subdivided
into M2a (activated by interleukin [IL]-4 or IL-13), M2b
(activated by immune complexes in combination with
IL-1β or lipopolysaccharide [LPS] and M2c (activated by
IL-10, transforming growth factor-β [TGFβ] or glucocorti-
coids). M1 macrophages are able to kill microorganisms
as well as tumor cells and secrete high levels of pro-
inflammatory cytokines and tumoricidal agents, reactive
nitrogen and oxygen intermediates , whereas the M2-
derived chemokines play a role in the resolution of inflam-
mation through phagocytosis of apoptotic neutrophils,
reduced production of pro-inflammatory cytokines, and
increased synthesis of mediators important in tissue
remodeling, angiogenesis, and wound repair [4,5].
Considering the increasing interest for the role of
angiogenesis in the pathogenesis of rheumatic diseases,
such as rheumatoid arthritis, in this review we will focus
on the role of macrophages in angiogenesis associated
with rheumatic diseases.Angiogenesis
Angiogenesis is a process characterized by the formation
of newly formed capillaries from pre-existing bloodl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and antiangiogenic factors. About 30 angiogenic factors
have been described, such as vascular endothelial growth
factor (VEGF) family, fibroblast growth factor (FGF)
family, TGF-α and -β), platelet-derived growth factor
(PDGF), tumor necrosis factor alpha (TNF-α), angio-
genin, Interleukins (ILs), chemokines and angiopoietins
(Ang) [6,7]. On the other hand, several endogenous
antiangiogenic factors have been identified, including
angiostatin, endostatin, and thrombospondin (TSP).
An imbalance between these positive and negative
factors, with a prevalence of positive regulators, or a
downregulation of the expression of negative regulators,
is involved in pathological angiogenesis [6]. Physiological
angiogenesis is characterized by a cascade of events
which contains a number of distinct steps [8]. Angio-
genic factors induce endothelial cell production of pro-
teolytic enzymes, including matrix metalloproteinases
(MMPs) and plasminogen activators, which are involved
in the degradation of the basement membrane and of
the perivascular extracellular matrix. Successively, endo-
thelial cells proliferate and migrate into the perivascular
area forming “primary sprouts”. The subsequent
lumenation of these “primary sprouts” is responsible of
the formation of “capillary loops”. At the same time,
there is the synthesis of a new basement membrane,
which is the final stage of new vessel formation. Succes-
sively, endothelial cells of the “primary sprouts” prolifer-
ate and migrate to generate secondary and further
generations of sprouts.
In addition to this model, called “sprouting angiogen-
esis”, other models for angiogenesis have been described.
The so-called not sprouting angiogenesis or intussuscep-
tions is characterized by a column of interstitial cells
which divides the lumen of a pre-existing vessel in two
parts forming two vessels [9]. In tumors, other angiogenic
mechanisms have been seen, such as vasculogenic mimi-
cry and the formation of mosaic vessels. In vasculogenic
mimicry, transdifferentiation of cancer cells allowing them
to form tubular structures occurs. Mosaic vessels are char-
acterized by the cooperation between endothelial cells and
tumor cells to form new vessels [10,11].
Angiogenesis is involved in the pathogenesis of several
diseases, including chronic inflammatory diseases. In
fact, inflammatory infiltrates and newly-formed vessels
have been described in chronic inflammatory diseases,
including rheumatoid arthritis and vasculitides. In these
pathological conditions, angiogenesis support inflamma-
tory cells recruitment and determines a compensatory
response to ischemia and to the augmented metabolic
activity [12,13]. In fact, angiogenic agents promote
endothelial cell expression of adhesion molecules and
inflammatory cytokines and chemokines. VEGF may
induce endothelial cells to express adhesion molecules,such as vascular cell adhesion molecule-1 (VCAM-1) and
intercellular adhesion molecule-1 (ICAM-1), allowing the
migration of monocytes and lymphocytes into the ex-
tracellular matrix [14,15]. Angiogenic factors, such as
chemokines containing the ELR motif (glutamyl-leucyl-
arginyl sequence), and CXC chemokines, are responsible
for inflammatory cells recruitment [16,17]. Moreover,
FGF-1 and FGF-2 favor migration of inflammatory cells
via inducing endothelial cell to produce plasminogen
activator and collagenase which are responsible for the
degradation of the extracellular matrix [18].
It is interesting to note that most angiogenic agents, such
as TNF-α, IL-1, IL-6, IL-8, and IL-18 are also inflammatory
factors which are involved in increasing the production of
other inflammatory cytokines and cell adhesion molecules,
and in improving matrix cyclooxygenase activity and
MMPs [19].
MMPs are secreted or membrane-anchored zinc-
dependent endopeptidases, which are involved in the
degradation of components of the extracellular matrix.
Remodeling of the extracellular matrix by MMPs is
important in angiogenesis. Among the various subtypes
of MMPs, MMP-1, MMP-2 and MMP-9 expression
levels have been demonstrated in rheumatoid synovial
macrophages [20,21]. Moreover, synovial macrophages
also express tissue inhibitors of MMPs (TIMPs) that
contrast the effects of MMPs [20].
Members of the Wnt protein family have been shown
to regulate several biological processes even if only
recently its role in angiogenesis has been demonstrated
[22,23]. By considering that both macrophages and
secreted Wnt proteins regulate angiogenesis, it has been
recently hypothesized that Wnt ligands mediate some of
the effects that macrophages have on angiogenesis [2].
An augmented activation of Wnt5a has been seen in
macrophages exposed to inflammatory agents, including
interferon-γ (IFN-γ) and lipopolysaccharide (LPS) [2].
Moreover, Wnt5a may be responsible for inducing macro-
phage expression of numerous angiogenic cytokines, in-
cludingIL-6, IL-8 and IL-1β [20]. Wnt5a is also involved
in inducing endothelial cell production of the monocyte
chemoattractant protein-1 (MCP-1)/CCL2 [24].
On the other hand, there are evidences that Wnt
proteins may mediate also antiangiogenic effects, pro-
bably because angiogenesis is characterized by different
morphological changes required at different stage [2,25].
Thus, it is possible that the same protein may be angio-
genic or antiangiogenic factor depending on the stage of
angiogenesis at which it is present [2]. Furthermore,
Wnt signal may be influenced by other pathways, such
as VEGF, Ang-1 and ang-2, Notch/Dll4, and focal
adhesion kinase (FAK) [26]. Moreover, differential Wnt
receptor expression has been hypothesized in cells res-
ponding to the signal [2].
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Many angiogenic factors have been demonstrated in
rheumatoid arthritis synovium, including CXC chemo-
kines containing the ELR motif [27,28]. They bind to
endothelial cells via specific endothelial chemokine re-
ceptors, such as CXCR2. In rheumatoid arthritis, CXCR2
has been demonstrated in synovial-tissue macrophages.
CXCR2 is involved in monocyte recruitment from the
circulation via binding to MCP-1/CCL2 [27,29,30]. Fur-
thermore, CXCR2 recognizes important inflammatory
chemokines, including growth-regulated oncogene a
(groa)/CXCL1, IL-8/CXCL8, epithelial-neutrophil acti-
vating protein-78 (ENA-78)/CXCL5, connective tissue-
activating peptide-III (CTAP-III)/CXCL7 and granulo-
cyte chemotactic protein 2 (GCP-2)/CXCL6 [27,29,31].
Moreover, synovial-tissue macrophages express also
CXCR4, the receptor of another important angiogenic
chemokine, namely specific receptor for stromal cell-
derived factor-1 (SDF-1)/CXCL12 [27,29].
Macrophage-derived angiogenic chemokines identified
in rheumatoid arthritis synovial tissue include ENA-78
/CXCL5 [32], a chemokine involved in the chemotaxis of
neutrophils [33,34]. Fractalkine/CX3CL1, another chemo-
kine produced by synovial macrophages, is involved in cell
adhesion and in chemotaxis of monocytes and lym-
phocytes [27,29,35]. Groa/CXCL1, CTAP-III/CXCL7, and
MCP-1/CCL2 [27,35,36], and macrophage inflammatory
protein-1α (MIP-1α)/CCL3, responsible of apoptosis inhi-
bition, increases macrophage and neutrophils infiltration,
and induces angiogenesis in synovial tissue [37].
In rheumatoid arthritis synovium, macrophages may
be activated by T cells via cell-cell contact. Moreover,
numerous soluble mediators are involved in macrophage
activation. In fact, immune complexes promote macro-
phage activation through the binding to FcγRs. Further-
more, peptidoglycans, LPS and heat-shock proteins may
induce macrophage activation via binding to Toll-like
receptors [38,39]. Activated macrophages are responsible
for production of numerous angiogenic cytokines and
growth factors. In rheumatoid arthritis synovial tissue,
macrophages release VEGF through TNF-α, TGF-α, and
IL-1 stimulation [40]. VEGF plays a key role in induction
and amplification of angiogenic response [41]. VEGF
receptors (VEGFRs) are expressed on macrophages,
including constitutive expression of VEGFR-1, -3, and
inducible expression of VEGFR-2. There are evidences
that VEGFRs have a role in the recruitment of macro-
phages in various inflammatory conditions [41-46]. In
rheumatoid arthritis, VEGFR-1 is responsible for macro-
phage activation and angiogenesis [27,28,47]. Moreover,
VEGFR-1 deficiency results in decreased disease severity
and diminished macrophage functions, such as phago-
cytosis and the secretion of IL-6 and VEGF-A, in murinemodels of arthritis [47]. Chung et al. [48] have
hypothesized that VEGFR-3-specific signaling can
induce new blood vessels, through the involvement of
macrophages.
Other important macrophage-derived angiogenic
factors are IL-15, IL-17, IL-18, TNF-α, FGF, PDGF, and
IL-8 that enhances the expression of leukocyte adhesion
molecule [27,28,33,49-51]. IL-15 and IL-18 are involved
in T helper 1 polarization and, as recently demonstrated,
IL-18 is also responsible for inducing macrophage pro-
duction of MCP-1/CCL2 [52]. Among various PDGF
isoforms, only PDGF-C and PDGF-D, and not PDGF-A
and PDGF-B, are expressed by synovial fibroblasts and
macrophages in rheumatoid arthritis synovial mem-
brane. Moreover, PDGF-D induces synovial fibroblast
proliferation and expression of MMP-1 [53]. Carmi
et al. [54] have demonstrated that macrophage-derived
IL-1β initiates angiogenesis by recruitment of cells of
myeloid and endothelial lineages, especially in hypoxic
condition.
In rheumatoid arthritis, hypoxia is induced by the high
metabolic demands of synovial inflammation. An in-
creased number of macrophages has been demonstrated
in hypoxic tissues, such as synovial membrane, where
hypoxia induces VEGF production by macrophages and
other cells [27,28,55]. In fact, expression of hypoxia
inducible factor-1α (HIF-1α) by macrophages has been
found in rheumatoid synovial membrane, mostly close
to the intimal layer and in the subintimal area [56]. The
reduced intra-articular PO2 is responsible for inducing
HIF-1α expression, which, in turn, induces synovial cells,
macrophages, and other inflammatory cells to produce
VEGF [57].
Moreover, macrophage migration-inhibitory factor
(MIF) is expressed by macrophages in the synovium,
where it is responsible for inducing macrophage pro-
duction of angiogenic agents, including TNF-α, IL-1,
IL-6, IL-8/CXCL8 and MMPs production [21,39]. In
animal models of rheumatoid arthritis, MIF antagonism
or deficiency result in decreased disease severity [58].
IL-6, LPS, IL-1β, IFN-α, IFN-γ and TNF-α induce
CCAAT/enhancer-binding protein D (CEBPD) expres-
sion in rheumatoid arthritis [20,59-63]. CEBPD is a
member of the family of the basic leucine zipper domain
transcription factors, involved in tissue differentiation,
metabolism and immune response. CEBPD activation in
macrophage can promote angiogenesis [63], probably via
activation of CEBPD-responsive factors, such as groa/
CXCL1 and TNFAIP6 [64,65]. Groa/CXCL1 promotes
microvascular endothelial cell tube formation in vitro
[63,65]. TNFAIP6 contains a hyaluronan-binding LINK
domain and a CUB (complement subcomponents C1r/
C1s, Uegf, BMP-1) domain. The LINK domain, probably
through inhibition of MMPs and aggrecanase enzymes,
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of inflammation and arthritis [63,64,66-68]. Thus, the
angiogenic effect of TNFAIP6 is probably related to
extracellular matrix remodeling to achieve regulation of
vascular formation [63].
On the other hand, macrophages are involved in the
production of important antiangiogenic factors, such as
IP-10/CXCL10, Mig/CXCL9, IFN-γ, TIMPs, and TSP2.
In rheumatoid arthritis, macrophages produce TSP2 in
the lining layer and in the stroma of diffuse synovitis.
On the contrary, macrophages do not produce TSP2
when they are organized in lymphoid microstructures.
In fact, the less aggressive pattern of rheumatoid arth-
ritis is characterized by diffuse synovitis and absence of
organized lymphoid microstructures [69,70]. Moreover,
macrophages may produce IL-27, a cytokine expressed
in rheumatoid arthritis synovium [70,71]. Using a
murine model of collagen-induced arthritis (CIA),
Pickens et al. [72] have demonstrated that IL-27
expression results in reduced synovial vasculature,
probably due to downregulation of IL-17 levels in
joints with forced IL-27 expression. IL-27 over-
expression is responsible for inhibiting IL-1β and IL-6
production, and this leads to a reduced T helper-17
activity characterized by decreased IL-17 expression.
Low levels of IL-17 are responsible for a decreased
synovial production of macrophage-derived angiogenic
factors, such as groa/CXCL1, ENA-78/CXCL5, and
MCP-1/CCL2.The role of macrophages in angiogenesis in other
rheumatic diseases
Studies on the role of macrophages in angiogenesis in
other rheumatic diseases are very scarce. In osteoarth-
ritis, angiogenesis enhances inflammation and contri-
butes to the severity of the disease. Angiogenesis may
be found in osteochondral junction and synovium
from patients with osteoarthritis, where macrophages
may contribute to angiogenesis via VEGF expression
[73,74]. A role of VEGF has been described in psori-
atic arthritis and ankylosing spondylitis [75]. In sys-
temic sclerosis, VEGF has been detected in sera of
patients, even if the role of angiogenesis is controver-
sial [75,76]. VEGF, epidermal growth factor (EGF),
FGF and IL-18 have been found in sera of patients
affected by systemic lupus erythematosus [75,77].
Several studies have demonstrated that angiogenesis
plays a key role in the pathogenesis of vasculitides, such
as giant cell arteritis, thromboangiitis obliterans, Kawasaki
syndrome, Churg-Strauss syndrome, Wegener granuloma-
tosis, microscopic polyangiitis, and Behcet disease. The
angiogenic response is more evident in small vessel vascu-
litides than in medium- and large-vessels vasculitides,since angiogenesis generally involves capillary and post-
capillary venules.
In vasculitides, angiogenesis may represent a compen-
satory response to ischemia and to increased metabolic
activity principally in acute phase of disease [78]. A role
for VEGF, FGF-2, TGF-β, PDGF, TNF-α, MCP-1, IL-6
and IL-8 have been described in giant cell arteritis
[79,80]. Multinucleated giant cells (MGCs) are special-
ized fused cells derived by macrophages, which have
been found in media-intima of arterial walls from
patients affected by giant cell arteritis [81]. MGCs pro-
duce numerous angiogenic factors, such as VEGF and
PDGF, and may be also involved in elastic membranes
degradation via MMP-2 production [82-85].
In thromboangiitis obliterans, increased levels of TNF-
α have been found in vascular lesions [86]. VEGF and
TGF-β overexpression has been found in Kawasaki
syndrome [75], and TGF-β1 upregulates VEGF expres-
sion in acute phase of disease [87].
Increased levels of TGF-β are also been detected in sera
of patients affected by ANCA associated vasculitides, such
as Churg-Strauss syndrome, Wegener granulomatosis,
and microscopic polyangiitis [75,77].
In Behcet disease, increased IL-8 expression has
been found in synovial fluids. Moreover, increased
VEGF levels has been demonstrated in oral aphthous
lesions, in the ocular inflammation and in blood serum
[88-91].Macrophage: a therapeutic target in rheumatic diseases
Macrophage-derived chemokine production and pa-
thological angiogenesis in rheumatic diseases may be
suppressed by several antirheumatic drugs, including
methotrexate, sulfasalazine, leflunomide, chloroquine,
and anti-TNF agents [27-29]. These compounds may
inhibit synovial vessel formation by nonspecifically
blocking the action of angiogenic mediators [27,75]. A
more favorable response after intra-articular glucocorti-
coid therapy or radiation synovectomy has been des-
cribed in synovial membrane characterized by elevated
synovial macrophage number [92]. Inhibition of TNF-α,
IL-1β and IL-6 has been described in LPS stimulated
human monocyte/macrophage after incubation with
chloroquine [93]. Infliximab, a chimeric monoclonal
antibody directed against TNF-α, in combination with
methotrexate, leads to decreased synovial and skin
VEGF expression in patients affected by psoriatic arth-
ritis [94]. Moreover, the anti-IL-6 receptor antibody
tocilizumab may reduce VEGF production in rheu-
matoid arthritis [95]. Thalidomide, recently introduced
into the treatment of rheumatoid arthritis and lupus, is
responsible for angiogenesis and TNF-α inhibition
[27,75].
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ine models has been seen after treatment with antibodies to
macrophage-derived angiogenic chemokines, including
IL-8, ENA-78/CXCL5, MIP-1α/CCL3, MCP-1/CCL2, and
fractalkine [35,96,97]. Several oral chemokine receptor
antagonists, including CXCR2 and CXCR4 inhibitors,
have been tried in human rheumatoid arthritis as
well as in animal models of arthritis [98]. Moreover,
numerous chemokine receptor antagonists, including
the nonpeptide antagonist of the murine CCR1, called
J-113863, have reduced articular inflammation in mur-
ine collagen-induced arthritis, together to a reduction
of TNF-α production by macrophages [99]. Encour-
aging results have been also seen in humans treated with a
CCR1 antagonist in a phase Ib clinical trial [100]. Imatinib
mesylate, a competitive tyrosine-kinase inhibitor used in
the treatment of numerous hematological malignancies,
seems to inhibit macrophage activation, osteoclastogenesis
and joint damage in murine models of collagen-induced
arthritis [101,102]. Dehydroxymethylepoxyquinomicin,
a newly developed compound that inhibits nuclear
factor κB activation, may inhibit macrophage cytokine
production and suppress murine collagen-induced
arthritis [103].
HIF-mediated angiogenesis may be a further target.
YC-1, a superoxidesensitive stimulator of soluble
guanylyl cyclase initially used as vasodilator in hyper-
tension and thrombosis treatment, also diminishes HIF-Figure 1 Chemokines, growth factors and cytokines involved in the a1α expression and activity [104,105]. Paclitaxel, a mitotic
inhibitor used in cancer chemotherapy, is also a HIF-1
inhibitor which has been proposed in rheumatoid
arthritis treatment [104,106].Conclusions
Angiogenesis is emerging key player in pathogenesis of
several rheumatic diseases, such as rheumatoid arthritis,
osteoarthritis, ankylosing spondylitis, systemic sclerosis,
systemic lupus erythematosus, and vasculitides. Among
major cell types involved in angiogenesis, macrophages
are known to produce numerous angiogenic factors,
including VEGF, FGF, TGF-β, PDGF, TNF-α, MCP-1,
IL-6, IL-8, and IL-18 (Figure 1).
Much research has been concentrated on the role of
macrophage derived angiogenic factors in rheumatoid
arthritis. Nevertheless, it is conceivable that macrophage
may be involved in angiogenesis in other rheumatic dis-
eases characterized by the presence of angiogenic factors
which may be produced by macrophage, although not
exclusively.
This suggests that macrophage could be usefully
selected as a therapeutic targets of an antiangiogenic
therapy in the treatment of rheumatic diseases, even
if further studies are needed to better elucidate the
exact role of macrophage in angiogenesis in these
diseases.ngiogenic activity of macrophages.
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